Education
About Us
Working with TipRanks
Follow Us
Abeona Therapeutics (ABEO)
NASDAQ:ABEO
Top Page
Abeona Therapeutics
(NASDAQ:ABEO)
Select Model
Select Model
Rating:60Neutral
Price Target:
$5.50
▲(6.59% Upside)
The score is held back mainly by weak operating performance and persistent cash burn despite a stronger balance sheet. Offsetting this, the latest earnings call reflected solid commercial and reimbursement progress for ZivaSkin, and technicals show modest near-term momentum, while valuation appears optically low but is tempered by earnings-quality concerns.
Positive Factors
Potential FDA Approvals
Anticipated FDA approvals for key therapies could significantly enhance Abeona's market position and revenue potential, marking a pivotal shift from a clinical-stage to a revenue-generating company.
Significant Revenue Potential
Projected revenue from pz-cel treatments represents a substantial financial opportunity, potentially transforming Abeona's financial landscape and supporting long-term growth.
Strong Manufacturing Capabilities
Robust in-house manufacturing capabilities ensure control over production processes, reducing dependency on external partners and supporting scalable growth.
Negative Factors
Ongoing Financial Challenges
Persistent financial struggles, including ongoing losses and negative cash flows, pose risks to Abeona's sustainability and ability to fund operations without external financing.
Increased General and Administrative Expenses
Rising administrative costs due to launch preparations could strain financial resources, impacting profitability and necessitating careful cost management.
Supply Gated Launch
Initial supply constraints could limit revenue generation and market penetration, delaying the realization of full financial benefits from new product launches.
Abeona Therapeutics (ABEO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$282.88M
Dividend YieldN/A
Average Volume (3M)1.10M
Price to Earnings (P/E)4.4
Beta (1Y)0.83
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees136
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.10
Shares Outstanding54,191,360
10 Day Avg. Volume713,049
30 Day Avg. Volume1,095,900
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)5.19
Price to Sales (P/S)0.00
P/FCF Ratio-3.91
Enterprise Value/Market Cap0.36
Enterprise Value/Revenue257.63
Enterprise Value/Gross Profit-106.90
Enterprise Value/Ebitda1.15
Forecast
1Y Price Target
$23.75Price Target Upside360.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.13
Revenue Forecast (FY)$111.09M
Abeona Therapeutics Business Overview & Revenue Model
Company DescriptionAbeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
How the Company Makes MoneyAbeona Therapeutics generates revenue primarily through strategic partnerships, grants, and licensing agreements related to its proprietary technologies and product candidates. The company may receive upfront payments, milestone payments, and royalties from these collaborations as their therapeutic products progress through clinical development and towards commercialization. Abeona's focus on rare genetic disorders often attracts funding from non-profit organizations and governmental bodies interested in supporting the advancement of novel treatments for these conditions. Additionally, successful commercialization of their therapies, if achieved, would provide direct revenue from product sales.
Abeona Therapeutics Earnings Call Summary
Earnings Call Date:Nov 12, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Mar 23, 2026
Earnings Call Sentiment Positive
The call conveyed a generally positive outlook for Abeona Therapeutics, with strong advancements in the commercial launch of ZivaSkin, expansion of treatment centers, and favorable market access. However, there were notable challenges, including delays in patient treatment and increased SG&A expenses. The company's financial position remains strong, and its pipeline shows promising advancements.Q3-2025 Updates
Positive Updates
ZivaSkin Commercial Launch Progress
Patient demand for ZivaSkin is increasing, with product order forms received for 12 patients. The number of identified eligible patients at qualified treatment centers has more than doubled to approximately 30.
Expansion of Qualified Treatment Centers
Children's Hospital Colorado has been added as a new qualified treatment center, bringing the total to three. Discussions are ongoing with other centers to expand the network further.
Strong Market Access for ZivaSkin
Positive coverage decisions from major commercial and government payers have been secured, covering over 80% of commercially insured lives. ZivaSkin has baseline coverage across all state Medicaid programs, and a permanent product J code will be effective from January 2026.
Financial Stability
The company has a robust cash position of $207.5 million, expected to fund operations for over two years without anticipated revenue from ZivaSkin. The net loss decreased significantly to $5.2 million from $30.3 million in the previous year.
Pipeline Advancements
The company's gene therapy program for X-linked retinoschisis is part of the FDA Rare Disease Endpoint Advancement pilot program. Additionally, Dr. James A. Gao has been appointed as Senior Vice President, Head of Clinical Development and Medical Affairs.
Negative Updates
Delay in First Patient Treatment
The first patient treatment for ZivaSkin was delayed to 2025 due to a performance issue in a release assay, which required optimization and regulatory submissions.
Increased SG&A Expenses
Selling, general, and administrative expenses increased to $19.3 million from $6.4 million in the previous year, reflecting reclassified R&D expenses and increased headcount and professional costs.
Temporary Manufacturing Pause
A temporary pause in patient biopsies was implemented to ensure product quality, impacting the timeline for patient treatments.
Company Guidance
During the Abeona Therapeutics third quarter 2025 conference call, the company provided guidance on its ZivaSkin launch, highlighting key metrics. ZivaSkin is the first autologous cell-based gene therapy for recessive dystrophic EB (RDEB) and is experiencing growing patient demand with 12 ZivaSkin Product Order Forms received and approximately 30 eligible patients identified at Qualified Treatment Centers (QTCs). The company expanded its QTC network to three centers, including Children's Hospital Colorado. On the market access front, ZivaSkin gained coverage from major commercial payers covering over 80% of insured lives, and it now has baseline coverage across all 51 state Medicaid programs. Furthermore, CMS will establish a permanent product J code effective January 1, 2026, to facilitate reimbursement processes. Financially, Abeona reported a net loss of $5.2 million for the quarter with cash and investments totaling $207.5 million as of September 30, 2025, which is expected to fund operations for over two years.Abeona Therapeutics Financial Statement Overview
Summary
Abeona Therapeutics exhibits significant financial challenges, characterized by consistent losses, lack of revenue growth, and negative cash flows. Despite manageable debt levels, the company's financial health is at risk without a turnaround in operational performance and revenue generation.Income Statement
Abeona Therapeutics shows a concerning trend with no revenue in the latest year, indicating potential challenges in product commercialization. The persistent negative net profit margin and declining EBIT and EBITDA margins reflect ongoing operational struggles and financial losses over recent years.Balance Sheet
The balance sheet indicates a moderate financial position with a relatively low debt-to-equity ratio, suggesting manageable leverage. However, the shrinking equity base and decreasing return on equity highlight challenges in value creation and financial returns for investors.Cash Flow
Cash flow analysis reveals negative free cash flow growth and a declining operating cash flow to net income ratio, underscoring liquidity challenges. The reliance on financing activities suggests potential sustainability concerns without generating positive cash flow from operations.| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 400.00K | 0.00 | 3.50M | 1.41M | 3.00M | 10.00M |
| Gross Profit | -964.00K | -2.91M | 1.90M | 964.00K | 3.00M | 10.00M |
| EBITDA | 89.85M | -56.62M | -50.57M | -34.38M | -76.82M | -74.52M |
| Net Income | 82.35M | -63.73M | -54.19M | -39.70M | -84.94M | -84.23M |
Balance Sheet | ||||||
| Total Assets | 231.09M | 108.93M | 64.00M | 64.21M | 79.59M | 151.20M |
| Cash, Cash Equivalents and Short-Term Investments | 207.46M | 97.72M | 52.23M | 52.15M | 45.02M | 95.03M |
| Total Debt | 24.11M | 23.05M | 5.40M | 7.63M | 9.38M | 8.73M |
| Total Liabilities | 59.86M | 64.90M | 49.18M | 37.45M | 37.22M | 48.65M |
| Stockholders Equity | 171.23M | 44.03M | 14.83M | 26.76M | 42.37M | 102.55M |
Cash Flow | ||||||
| Free Cash Flow | -82.36M | -58.46M | -37.34M | -43.61M | -69.82M | -36.35M |
| Operating Cash Flow | -74.93M | -56.02M | -37.01M | -43.48M | -65.67M | -35.02M |
| Investing Cash Flow | 114.35M | -39.24M | 208.00K | -23.96M | 66.06M | -83.71M |
| Financing Cash Flow | 27.74M | 104.14M | 37.06M | 43.17M | 24.86M | 1.94M |
Abeona Therapeutics Technical Analysis
Negative
5.16
Price Trends
4.92
Positive
5.49
Negative
5.66
Negative
Market Momentum
0.09
Positive
50.55
Neutral
38.58
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ABEO, the sentiment is Negative. The current price of 5.16 is below the 20-day moving average (MA) of 5.24, above the 50-day MA of 4.92, and below the 200-day MA of 5.66, indicating a neutral trend. The MACD of 0.09 indicates Positive momentum. The RSI at 50.55 is Neutral, neither overbought nor oversold. The STOCH value of 38.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ABEO.
Abeona Therapeutics Risk Analysis
Abeona Therapeutics disclosed 48 risk factors in its most recent earnings report. Abeona Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Abeona Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $282.88M | 4.43 | 75.90% | ― | ― | ― | |
56 Neutral | $280.10M | -3.43 | ― | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $231.81M | -0.03 | ― | ― | ― | -1072.48% | |
45 Neutral | $204.58M | -4.52 | ― | ― | ― | 82.23% | |
44 Neutral | $250.18M | -5.83 | ― | ― | ― | 18.82% |
* Healthcare Sector Average
ABEO
Abeona Therapeutics
5.16
-0.80
-13.42%
GALT
Galectin Therapeutics
3.45
2.32
205.31%
SLN
Silence Therapeutics
5.73
-0.61
-9.62%
HUMA
Humacyte
1.08
-3.60
-76.92%
VOR
Vor Biopharma
11.67
-20.93
-64.20%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.